Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 27;12(4):747.
doi: 10.3390/biomedicines12040747.

Aldose Reductase as a Key Target in the Prevention and Treatment of Diabetic Retinopathy: A Comprehensive Review

Alexandra-Ioana Dănilă  1 , Laura Andreea Ghenciu  2 , Emil Robert Stoicescu  3   4   5   6 , Sorin Lucian Bolintineanu  1 , Roxana Iacob  1   3   4 , Mihai-Alexandru Săndesc  7 , Alexandra Corina Faur  1
Affiliations
Review

Aldose Reductase as a Key Target in the Prevention and Treatment of Diabetic Retinopathy: A Comprehensive Review

Alexandra-Ioana Dănilă et al. Biomedicines. .

Abstract

The escalating global prevalence of diabetes mellitus (DM) over the past two decades has led to a persistent high incidence of diabetic retinopathy (DR), necessitating screening for early symptoms and proper treatment. Effective management of DR aims to decrease vision impairment by controlling modifiable risk factors including hypertension, obesity, and dyslipidemia. Moreover, systemic medications and plant-based therapy show promise in advancing DR treatment. One of the key mechanisms related to DR pathogenesis is the polyol pathway, through which aldose reductase (AR) catalyzes the conversion of glucose to sorbitol within various tissues, including the retina, lens, ciliary body and iris. Elevated glucose levels activate AR, leading to osmotic stress, advanced glycation end-product formation, and oxidative damage. This further implies chronic inflammation, vascular permeability, and angiogenesis. Our comprehensive narrative review describes the therapeutic potential of aldose reductase inhibitors in treating DR, where both synthetic and natural inhibitors have been studied in recent decades. Our synthesis aims to guide future research and clinical interventions in DR management.

Keywords: aldose reductase; aldose reductase inhibitor; diabetic retinopathy; polyol pathway.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The polyol pathway.
Figure 2
Figure 2
Treatment options targeting aldose reductase inhibition.
See this image and copyright information in PMC

References

    1. Bourne R.R.A., Jonas J.B., Bron A.M., Cicinelli M.V., Das A., Flaxman S.R., Friedman D.S., Keeffe J.E., Kempen J.H., Leasher J., et al. Prevalence and Causes of Vision Loss in High-Income Countries and in Eastern and Central Europe in 2015: Magnitude, Temporal Trends and Projections. Br. J. Ophthalmol. 2018;102:575–585. doi: 10.1136/bjophthalmol-2017-311258. - DOI - PMC - PubMed
    1. Avogaro A., Fadini G.P. Microvascular Complications in Diabetes: A Growing Concern for Cardiologists. Int. J. Cardiol. 2019;291:29–35. doi: 10.1016/j.ijcard.2019.02.030. - DOI - PubMed
    1. Hoerger T.J., Harris R., Hicks K.A., Donahue K., Sorensen S., Engelgau M. Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. Ann. Intern. Med. 2004;140:689. doi: 10.7326/0003-4819-140-9-200405040-00008. - DOI - PubMed
    1. Tapp R.J., Shaw J.E., Harper C.A., De Courten M.P., Balkau B., McCarty D.J., Taylor H.R., Welborn T.A., Zimmet P.Z., on behalf of the AusDiab Study Group The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population. Diabetes Care. 2003;26:1731–1737. doi: 10.2337/diacare.26.6.1731. - DOI - PubMed
    1. Bebu I., Lachin J.M. Optimal screening schedules for disease progression with application to diabetic retinopathy. Biostatistics. 2018;19:1–13. doi: 10.1093/biostatistics/kxx009. - DOI - PMC - PubMed